A network of protein interactions determines polyglutamine toxicity.

Several neurodegenerative diseases are associated with the toxicity of misfolded proteins. This toxicity must arise from a combination of the amino acid sequences of the misfolded proteins and their interactions with other factors in their environment. A particularly compelling example of how profoundly these intramolecular and intermolecular factors can modulate the toxicity of a misfolded protein is provided by the polyglutamine (polyQ) diseases. All of these disorders are caused by glutamine expansions in proteins that are broadly expressed, yet the nature of the proteins that harbor the glutamine expansions and the particular pathologies they produce are very different. We find, using a yeast model, that amino acid sequences that modulate polyQ toxicity in cis can also do so in trans. Furthermore, the prion conformation of the yeast protein Rnq1 and the level of expression of a suite of other glutamine-rich proteins profoundly affect polyQ toxicity. They can convert polyQ expansion proteins from toxic to benign and vice versa. Our work presents a paradigm for how a complex, dynamic interplay between intramolecular features of polyQ proteins and intermolecular factors in the cellular environment might determine the unique pathobiologies of polyQ expansion proteins.

[1]  S. Tsuji,et al.  Genotype‐phenotype correlation in CAG‐repeat diseases , 2002, Neuropathology : official journal of the Japanese Society of Neuropathology.

[2]  S. Batalov,et al.  Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Saraste,et al.  FEBS Lett , 2000 .

[4]  Ronald Wetzel,et al.  Oligoproline effects on polyglutamine conformation and aggregation. , 2006, Journal of molecular biology.

[5]  Dimitri Krainc,et al.  Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.

[6]  G. Fink,et al.  Methods in enzymology vol 194 guide to yeast genetics and molecular biology , 1991 .

[7]  G. Fink,et al.  Methods in yeast genetics , 1979 .

[8]  H. Paulson,et al.  Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Lindquist,et al.  Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Paolo Guidetti,et al.  A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease , 2005, Nature Genetics.

[11]  Zoya Ignatova,et al.  Extended Polyglutamine Tracts Cause Aggregation and Structural Perturbation of an Adjacent β Barrel Protein* , 2006, Journal of Biological Chemistry.

[12]  D. Housman,et al.  Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Olson,et al.  Altered transcription in yeast expressing expanded polyglutamine , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. O’Shea,et al.  Global analysis of protein localization in budding yeast , 2003, Nature.

[15]  H. Lehrach,et al.  A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. , 2004, Molecular cell.

[16]  H. Zoghbi,et al.  Glutamine repeats and neurodegeneration. , 2000, Annual review of neuroscience.

[17]  C. Soto,et al.  Protein misfolding and disease; protein refolding and therapy , 2001, FEBS letters.

[18]  P. Lansbury,et al.  Amyloid diseases: abnormal protein aggregation in neurodegeneration. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Christopher M Dobson,et al.  Principles of protein folding, misfolding and aggregation. , 2004, Seminars in cell & developmental biology.

[20]  Haibin Xia,et al.  siRNA-mediated gene silencing in vitro and in vivo , 2002, Nature Biotechnology.

[21]  M. Sudol,et al.  The importance of being proline: the interaction of proline‐rich motifs in signaling proteins with their cognate domains , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  E. Wanker,et al.  Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[24]  J. Weissman,et al.  A census of glutamine/asparagine-rich regions: implications for their conserved function and the prediction of novel prions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Housman,et al.  Evidence for a recruitment and sequestration mechanism in Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[26]  K. Fischbeck,et al.  Toxic Proteins in Neurodegenerative Disease , 2002, Science.

[27]  Peter Breuer,et al.  Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. , 2004, Molecular cell.

[28]  K. Fischbeck,et al.  CREB-binding protein sequestration by expanded polyglutamine. , 2000, Human molecular genetics.

[29]  Y. Chernoff,et al.  Huntingtin toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1 , 2002, The Journal of cell biology.

[30]  C A Ross,et al.  Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.

[31]  H. Paulson,et al.  RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia , 2004, Nature Medicine.

[32]  Ronald W. Davis,et al.  Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.

[33]  Gerald F. Tremblay Neuropathology , 1989, Neurology.

[34]  Susan Lindquist,et al.  Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein , 2003, Science.

[35]  Peter Bross,et al.  Protein misfolding and disease : principles and protocols , 2003 .

[36]  Susan Lindquist,et al.  Prions as adaptive conduits of memory and inheritance , 2005, Nature Reviews Genetics.

[37]  Susan Lindquist,et al.  Flanking sequences profoundly alter polyglutamine toxicity in yeast. , 2006, Proceedings of the National Academy of Sciences of the United States of America.